Mobile

A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Estud...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005074-12

A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Estudio abierto de fase 1b/2 con escalada de dosis de AMG 655 en combinación con AMG 479 en sujetos con tumores sólidos refractarios y avanzados

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part 1: To identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerated as determined by the incidence of dose limiting toxicity (DLT). Part 2: To estimate the efficacy, as measured by the objective response rate (ORR; confirmed complete response [CR] and partial response [PR] using modified Response Evaluation Criteria in Solid Tumors [RECIST]) of AMG 655 in combination with AMG 479.

Critère d'inclusion

  • Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. ------------------------------------------------------------ Parte 1:tumores sólidos refractarios y avanzados. Parte 2:Cáncer de pulmón no microcítico avanzado (CPNM), cáncer colorrectal (CRC), cáncer pancreático, cáncer de ovario o sarcoma

Liens